Mumbai: ZyCoV-D, the COVID-19 vaccine granted emergency use authorization by India’s drug regulator last month, will be produced in India by Karnataka-based Shilpa Medicare.
Cadila Healthcare, which has indigenously developed the first DNA plasmid COVID-19 vaccine for human use, said on Friday it has entered into an agreement with Shilpa Medicare for the production of ZyCoV-D.
“Cadilla Healthcare has entered into a definitive agreement with Shilpa Medicare, via its wholly owned subsidiary Shilpa Biologicals, for production-supply of the ZyCoV-D vaccine drug substance from its integrated biologics R&D cum manufacturing centre at Dharwad, Karnataka,” the drug firm said.
The production target of the vaccine will soon be mutually agreed upon by both parties.
“The company will transfer the ZyCoV-D technology to Shilpa Biologicals Pvt Ltd (SBPL). Under the agreement, SBPL will be responsible for manufacture of the drug substance of the vaccine, while the company is responsible for filling/packaging/distribution/marketing of the vaccine in its marketing territories,” Cadila Healthcare said.
ZyCoV-D, which has been cleared for the age group of 12-18, is expected to be rolled out next month.
